The report "Sepsis Diagnostics Market by Technology (Molecular Diagnostics, Microbiology, Immunoassay), Product (Instrument, Blood Culture Media), Method (Conventional & Automated), Usability (Laboratory & POC), Pathogen (Bacterial & Fungal) - Global Forecast to 2021", analyzes and studies the major market drivers, restraints, opportunities, and challenges in North America, Europe, Asia-Pacific, and the Rest of the world (RoW). —
On the basis of products, the global sepsis diagnostics market is segmented into 4 broad categories, namely, blood culture media, assay kits & reagents, instruments, and software.
The blood culture media market is estimated to command the largest share of the global sepsis diagnostics market in 2016. The large share of this segment can be attributed to the high use of blood culture testing as the standard diagnostic method for the diagnosis and identification of sepsis. The global assay kits & reagents segment, on the other hand, is expected hold the second largest share in the market owing to the increasing adoption of assay based kits and growing approvals for assay kit products across the globe.
Based on technology, the global sepsis diagnostics market is segmented as microbiology, immunoassays, molecular diagnostics, and flow cytometry. The global molecular diagnostic segment is expected to grow at the highest CAGR from 2016 to 2021. Its growth can be attributed to the increasing inclination of physicians and patients towards use of rapid diagnostic products for accurate and quick identification and diagnosis of sepsis. The global sepsis diagnostics market is also divided into two segments by method– conventional diagnostics and automated diagnostics. Furthermore, on the basis of usability, the sepsis diagnostics market is categorized into laboratory testing and point-of-care testing.
The sepsis diagnostics market on the basis of pathogen is segmented into bacterial sepsis, fungal sepsis, and other infectious pathogens (viral and parasitic infection). The bacterial sepsis segment is expected to account for a larger share (85.7%) of the sepsis diagnostics market in 2016.
Key factors such as rising geriatric population, growing number of surgical procedures, high incidence of hospital-acquired infections, and growth in the number of product approvals are supporting the growth of this market. On the other hand, lack of standard protocols and awareness and shortage of skilled staff are the major challenges in this market.
As of 2016, North America holds the largest share of the global sepsis diagnostics market, followed by Europe. However, the Asia-Pacific market is expected to grow at the highest CAGR of 11.9% from 2016 to 2021. A number of factors such as increasing number of surgical procedures, growing number of clinical studies, developing healthcare infrastructure, and rising focus of global players in this region are propelling the growth of the Asia-Pacific sepsis diagnostics market.
bioMérieux SA (France), T2 Biosystems, Inc. (U.S.), Cepheid (U.S.), Thermo Fisher Scientific Inc. (U.S.), Nanosphere, Inc. (U.S.), Abbott Laboratories, Inc. (U.S.), Roche Diagnostics Limited (Switzerland), Becton, Dickinson and Company (U.S.), Bruker Corporation (U.S.), and Beckman Coulter, Inc. (U.S.) are some of the key players operating in the sepsis diagnostics market.
Email: Send Email
Address: 701 Pike Street Suite 2175, Seattle, WA 98101, United States
Release ID: 143920